Global Preventive Vaccines Market- Trends and Forecasts 2017 - 2022

  • ID: 4387255
  • Report
  • Region: Global
  • 197 pages
  • Mordor Intelligence
1 of 3
The global preventive vaccines market accounted for a value of USD 27.6 billion in 2015 and is expected to reach USD 55 billion by 2021, growing at a CAGR of 12.4% during the forecast period from 2016 to 2021.

The vaccines market is different from any other commodity market. Compared to the pharmaceutical market, the vaccines market is relatively small, although growing fast. The vaccines market is rather concentrated on both supply and demand sides. It is highly regulated and largely dependent on public purchasers and donor policies. The vaccines market has very distinct features that increase the complexity of assessing and understanding pricing and procurement in their context. It is made up of individual markets for individual vaccines or vaccine types, each with its own specificities, particularly on the supply side.

New candidates for vaccination against cancer and HIV, which are under development, are also projected to hit the magical milestone. Multinational vaccine companies historically have conducted much of the innovation, research, and development in the field of vaccine production. The companies have used their significant revenues, global size, and deeper expertise to fund these R&D efforts. New technologies are also being introduced to curb the time and expense incurred on new vaccine discovery and production. However, despite the success of vaccines, infectious diseases are still a major cause of illnesses worldwide. At least 40 major infectious diseases are still uncontrolled by vaccination.

Global Preventive Vaccines Market- Market Dynamics

This study targets gaining a detailed overview of the dynamics of the preventive vaccines market during the forecast period. It focuses on the need to develop strategic insights into the global and country-level markets, taking into consideration the demand as a result of awareness, government initiatives, birth rate etc. A holistic study of the market has been carried out by incorporating various factors extending from country-specific demographic conditions and market-specific microeconomic influences that were needed to analyze the future trends of this market.

Drivers

The report details several factors driving the growth of the global preventive vaccines market. Some of these are:

Increasing number of products

Increasing awareness

Increasing investments in R&D

Technological advancements

Increasing government funded projects and associations promoting vaccination

Growing demand in the developing countries (China and India) of the Asia-Pacific region

Restraints

High regulatory intervention and costs are turning out to be the major restraints for this market.

The market has been segmented based on the type of vaccines and application. The segment based on the type of vaccine includes live, attenuated vaccine, inactivated vaccines, subunit vaccine, toxoid vaccines, conjugate vaccines, DNA vaccine, and recombinant vector vaccine. The market segment based on applications has been further subdivided into pediatric vaccine and adult vaccine. The pediatric vaccines include pneumococcal vaccine, varicella vaccine, combination vaccines (Bivalent, trivalent, tetravalent, and pentavalent vaccines), MMR, poliovirus, hepatitis, HIB, and other pediatric vaccines. The segment on adult vaccines includes influenza, cervical cancer, hepatitis, zoster, and other adult vaccines.

There are currently close to 120 new vaccines in the pipeline of various companies across the globe, set to hit the market in the next five years. In anticipation of this and with the emergence of a new target market and smaller players in it, the global preventive vaccines market is set to grow at a CAGR of close to 12.4 % by the year 2021.

This Report Offers:
Market analysis for the global preventive vaccines market, with region-specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the global preventive vaccines market.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. INTRODUCTION
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and forecast period years
1.6 General Study Assumptions
2. RESEARCH METHODOLOGY
2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW AND INDUSTRY TRENDS
5.1 Current market scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of suppliers
5.2.2 Bargaining power of buyers
5.2.3 Degree of competition
5.2.4 Threat of substitution
5.2.5 Threat of new entrants
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 Market Drivers
6.1.1 Increasing demand, higher onset of diseases
6.1.2 Government funded projects and Associations
6.1.3 Higher profitability and improved technology
6.1.4 Hugh market demand
6.2 Market Restraints
6.2.1 Increasing demand for cost-effective vaccines
6.2.2 High regulatory intervention and cost
6.3 Market opportunities
6.3.1 New Target Populations-shift from established markets to lesser developed markets
6.4 Key Challenges
6.4.1 Difficult development process
7. GLOBAL PREVENTIVE VACCINES MARKET -SEGMENTATION
7.1 BASED ON TYPE OF VACCINE
7.1.1 LIVE, ATTENUATED VACCINES
7.1.2 INACTIVATED VACCINES
7.1.3 SUBUNIT VACCINE
7.1.4 TOXOID VACCINES
7.1.5 CONJUGATE VACCINES
7.1.6 DNA VACCINES
7.1.7 RECOMBINANT VECTOR VACCINES
7.2 BASED ON APPLICATION
7.2.1 PEDIATRIC VACCINE
7.2.1.1 PNEUMOCOCCAL VACCINES
7.2.1.2 VARICELLA VACCINES
7.2.1.3 COMBINATIONS VACCINES
7.2.1.3.1 BIVALENT VACCINES
7.2.1.3.2 TRIVALENT VACCINES
7.2.1.3.3 TETRAVALENT / QUADRIVALENT VACCINES
7.2.1.3.4 PENTAVALENT VACCINES
7.2.1.4 MMR
7.2.1.5 POLIOVIRUS
7.2.1.6 HEPATITIS
7.2.1.7 HIB
7.2.1.8 OTHER PEDIATRIC VACCINES
7.2.2 ADULT VACCINE
7.2.2.1 INFLUENZA
7.2.2.2 CERVICAL CANCER
7.2.2.3 HEPATITIS
7.2.2.4 ZOSTER
7.2.2.5 OTHER ADULT VACCINES
8. Global Preventive Vaccines market by Geography - Regional shares and forecasts
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East and Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of the Middle East and Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Merck & Co.
10.2 GlaxoSmithKline
10.3 Sanofi
10.4 Pfizer
10.5 Emergent BioSolutions
10.6 Takeda
10.7 Astellas Pharma
10.8 AstraZeneca
10.9 Mitsubishi Tanabe
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll